Year: 2025
Type: article
Abstract: Biosimilars produced in plant systems encompass a range of molecules, including antibodies, vaccines, enzymes, receptors, and other therapeutic molecules. In the present study, we aimed to express the immune checkpoint-inhibitor anti-CTLA-4 antibody, Ipilimumab, in Nicotiana tabacum plant. We generated transgenic tobacco plants using Agrobacterium-mediated transformation and purified an anti-CTLA-4 monoclonal antibody (mAbP CTLA-4) using protein A affinity chromatography. This purified mAbP CTLA-4 showed specific binding activity to CTLA-4-positive human tonsil tissues, as confirmed by immunoblot, indirect ELISA, and immunohistochemistry analyses. Our study confirmed that mAbP CTLA-4 effectively targeted CTLA-4 in human tonsil tissues. These findings suggest that our plant-derived anti-CTLA-4 antibody retains its original functionality, underscoring the promising potential of plant-based therapeutic expression systems for producing high-value medicinal biosimilars.
Source: Plant Biotechnology Reports
Language: English
Subfield: Biotechnology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,390
Award: G3289309817
OpenAlex ID: W4409182218